Rational Selection and Application of Ready-to-Use Formulations for Self-Emulsifying Drug Delivery Systems

Rational Selection
Poorly soluble drugs for oral administration present unique formulation challenges, particularly during early development. Formulation in a lipid-based carrier can be a feasible approach, but usually requires extensive testing to find suitable excipient combination.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Ensuring Integrity of Drug Formulation from Development to QC

pharmtech

After a small molecule has been identified as a viable drug candidate, substantial testing is required to assure that chemical and structural integrity are preserved throughout the drug development process to maintain its functionality. To keep a balance between quality and manufacturability, time-consuming and labor-intensive testing and analysis are required to demonstrate that chemical integrity is intact. Among the techniques used to study changes in chemical integrity are infrared and Raman spectroscopy. This webcast will discuss where efficiencies can be made in data collection, regulatory compliance, instrument qualification, method validation, and data integrity all along the development pipeline up to final quality control (QC) testing. Learn how to quickly identify changes in polymorphic structure, monitor API to excipient distribution, and troubleshoot out-of-specification (OOS) product lots, while preserving data integrity needed for audits.
Watch Now

Speed, Quality & Cost – Why You Should be Conducting Your Clinical Trials in Australia

pciservices

Speed, Quality & Cost – Why You Should be Conducting Your Clinical Trials. Join PCI Clinical Services and their partners for this educational webinar to learn tax incentive program and eligibility when conducting your trials in Australia
Watch Now

Gene Therapy for Rare Diseases: Considerations for Both Clinical and Post-Marketing Studies

Quanticate

There are approximately 7,000 distinct rare diseases affecting 350 million people worldwide, approximately 80 percent of which are caused by faulty genes. Scientific advances such as the CRISPR/Cas9 genome-engineering system have simplified the pharmaceutical and biotech industry’s ability to develop gene therapies, especially for single gene mutation disorders. The US Food and Drug Administration (FDA) has more than 700 active Investigational New Drug Applications (INDs) for gene and cell therapies and in 2017, the FDA approved two cell-based gene therapies and it is anticipated that gene therapy will become a mainstay treatment for many rare diseases.
Watch Now

FDA Drug Topics: Frequently Asked Questions about Labeling for Prescription Medicines

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians.
Watch Now